DexCom, Inc. (DXCM)

Market Cap	32.52B
Revenue (ttm)	4.15B
Net Income (ttm)	535.20M
Shares Out	392.11M
EPS (ttm)	1.33
PE Ratio	62.25
Forward PE	37.80
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,840,945
Open	83.70
Previous Close	83.58
Day's Range	82.58 - 84.49
52-Week Range	57.52 - 117.19
Beta	1.45
Analysts	Strong Buy
Price Target	98.50 (+18.78%)
Earnings Date	Jul 30, 2025

About DXCM

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Apr 14, 2005
• Employees: 10,300
• Stock Exchange: NASDAQ
• Ticker Symbol: DXCM
• Website: https://www.dexcom.com/global

Financial Performance

In 2024, DexCom's revenue was $4.03 billion, an increase of 11.34% compared to the previous year's $3.62 billion. Earnings were $576.20 million, an increase of 6.41%.

Analyst Summary

According to 20 analysts, the average rating for DXCM stock is "Strong Buy." The 12-month stock price target is $98.5, which is an increase of 18.78% from the latest price.

Price Target

$98.5

(18.78% upside)

Analyst Consensus: Strong Buy